In this first of a two-part podcast episode, Dr. Phillip Davis and Dr. Dan Stevens follow up on the symposium topic of “New Treatments for Prostate Cancer.” In Part I, Dr. Philip Davis explains molecular imaging, which uses a low dose of radioactive medicine to detect cancer and other diseases early, as well as providing doctors with both anatomic and functional information on the cancer cells. Dr. Dan Stevens details radioligand therapy, which uses radioactive isotopes to target cancer cells more precisely than traditional radiation therapy. Both technologies offer improved treatment options, enhancing patient outcomes.

Phillip Davis, MD, is a physician executive and new drug developer based in Charleston, South Carolina, with a background in general medicine and molecular imaging/nuclear medicine. Following completion of medical school and residency at the Medical University of South Carolina, he spent 10 years at the FDA in the Division of Medical Imaging and Radiation Medicine in Silver Spring, MD. He now leads US Clinical Development and supports Medical Affairs and New Asset Development at Blue Earth Diagnostics (BED), where he was the medical lead for a novel PET tracer approved by FDA in May of 2025.

Dan Stevens is a board certified (UK) pharmaceutical physician dedicated to translational science and drug development. He is a Fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians with a focus on novel oncology drug development and clinical development as they related to oncology and urology. Most recently, he has developed specific experience in targeted radioligand therapy.